版權(quán)說明：本文檔由用戶提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
HongzhiXu
ShandongProvincialHospital
MyeloproliferativeDisorders
CONTENTS
PathogenesisandmanagementofessentialthrombocythemiaIdiopathicerythrocytosis:adisappearingentityTherapeuticpotentialofJAK2inhibitorsPathogenesisandmanagementofessentialthrombocythemia
Severallinesofevidencesuggestablurringofthedistinctionbetweenthesedisorders.AproporationofpatientsdiagnosedwithET(seeTable1forcriteria)harborincreasedlevelsofbonemarrowreticulinintheabsenceofotherfeaturessuggestingadiagnosisofPMF
Thevariabledegreeofreticulinaccumulationreflectsthecombinedeffectsofgeneticbackground,diseaseduration,therapy,clonalburdenandtheacquisitionofadditionalgeneticlesions.Table1.Suggesteddiagnosticcriteriaforessentialthrombocythemia(ET)
DiagnosisrequiresA1-A3ORA1+A3-A5A1Sustainedplateletcount>450X109/L.A2Presenceofanacquiredpathogeneticmutation(eg,inJAK2orMPL).A3Noothermyeloidmalignancy,especiallypolycythemiavera(PV),primarymyelofibrosis(PMF),chronicmyeloidleukemia(CML)ormyelodysplasticsyndrome(MDS).A4Noreactivecauseforthrombocytosisandnormalironstores.A5Bonemarrowtrephinehistologyshowingincreasedmegakaryocyteswithprominentlargehyperlobatedforms;reticulinisgenerallynotincreased(≤2ona0-4scale).AreMutationsinJAK2Disease-initiatingEvents?TheacquisitionofaJAK2mutationwasprecededbyeitheradeletionofchromosome20q24oramutationinTET2.DirectevidencenowexistsdemonstratingthatJAK2mutationsarenotthedisease-initiatingeventinsomepatients,althoughthefrequencyofthisscenarioremainsunclear.
ProgressiontoAcuteMyeloidLeukemia
Progressiontoacutemyeloidleukemia(AML)occursinasmallminorityofETpatientsandinvolvestheaccrualoffurthergeneticevents.
DiagnosisandManagement
DiagnosticCriteria
MutationsinJAK2exon12arenotthoughttooccurinpatientswithET.Thecombinationofanisolatedthrombocytosiswithapathogeneticmutation,intheabsenceofirondeficiencyorfeaturesofPMF,isusuallysufficienttomakeadiagnosisofET.
Idiopathicerythrocytosis:adisappearingentity
ClassificationofErythrocytoses
Anerythrocytosiscanbeclassifieddependingontheidentifiedcause.Themaindivisionisonthebasisofprimarycauses,whereanintrinsicdefectintheerythroidprogenitorcellisassociatedwithanenhancedresponsetocytokines;orsecondary,wheretheincreasedredcellproductionisdrivenbyfactorsexternaltotheerythroidcompartment,suchasincreasederythropoietin(EPO)productionforanyreason.Primaryandsecondarycausescanbeclassifiedfurtheraseithercongenitaloracquired(Table2).Table2.CausesofanerythrocytosisPrimaryErythrocytosisSecondaryerythrocytosisIdiopathicerythrocytosisSecondaryerythrocytosisCongenitalDefectsoftheoxygensensingpathwayVHLgenemutation(Chuvash
erythrocytosis)PHD2mutationsHIF-2amutationsOthercongenitaldefectsHighoxygen-affinityhemoglobin
Bisphosphoglycerate
mutasedeficiency
AcquiredEPO-mediatedCentralhypoxiaChroniclungdiseaseRight-to-leftcardiopulmonaryvascularshuntsCarbonmonoxidepoisoningSmoker′serythrocytosisHypoventilationsyndromesincludingobstru-ctivesleepapneaHigh-altitude
LocalhypoxiaRenalarterystenosisEnd-stagerenaldiseaseHydronephrosisRenalcysts(polycystickidneydisease)Post-renaltransplanterythrocytosis
InvestigationofanErythrocytosis
Onceanerythrocytosishasbeenestablishedidentificationofthecauseisthenextfocus.
ClinicalConsequences
Araisedredcellcountwillincreasetheviscosityandthusmayhaveclinicalconsequences.
ManagementofanErythrocytosis
ReducingtheHctbyphlebotomy/venesectionreducesthebloodviscosityandmaybeofbenefit.CytoreductiveLow-doseaspirin
TherapeuticpotentialofJAK2inhibitors
TheV617Fmutationislocalizedinaregionoutsidetheadenosinetriphosphate(ATP)-bindingpocketofJAK2enzyme,ATP-competitiveinhibitorsofJAK2kinasearenotlikelytodiscriminatebetweenwild-typeandmutantJAK2enzymes.Therefore,JAK2inhibitors,byvirtueoftheirnearequipotentactivityagainstwild-typeJAK2thatisimportantfornormalhematopoiesis,mayhaveadversemyelosuppressionasanexpectedsideeffect,ifadministeredatdosesthataimtocompletelyinhibitthemutantJAK2enzyme.PreliminaryclinicalobservationsinselectedJAK2inhibitortrials.AgentCompanyTarget(s)JAKIC50(nM)CurrentphasePreliminaryclinicalobserbationsinmyelofibrosisstudiesINCB018424IncyteJAK1,JAK2JAK1=2.7*JAK2=4.5*JAK3=322*IIIDecreasedspleensizeirrespectiveofJAK2mutationalstatus;improvedqualityoflife,weightandperformance;decreasedinflammatorycytokinelevels.MyelosuppressionTG101384TargeGENJAK2JAK1=105JAK2=3JAK3=996IIDecreasedspleensize;decreaseinWBC.Myelosuppression;gastrointestinaldisturbanceXL019ExelixisJAK2JAK1=132JAK2=2JAK3=250discontinu
溫馨提示
- 1. 本站所有資源如無特殊說明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽，若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間，僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理，對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容，請(qǐng)與我們聯(lián)系，我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 二零二五年度法路往事房屋買賣中介傭金結(jié)算合同
- 二零二五年度用工協(xié)議與勞動(dòng)合同在勞務(wù)派遣合同中的風(fēng)險(xiǎn)控制
- 二零二五年度汽車抵押貸款購車二手車鑒定評(píng)估報(bào)告出具合同
- 二零二五年度私了后不追究責(zé)任企業(yè)并購合同終止及賠償協(xié)議
- 二零二五年度稻田土地承包經(jīng)營與品牌合作合同
- 2025年度頂賬房買賣與社區(qū)環(huán)境改善服務(wù)合同
- 二零二五年度瑜伽館與瑜伽文化傳播機(jī)構(gòu)合作合同
- 二零二五年度空調(diào)設(shè)備保養(yǎng)與智能化系統(tǒng)集成合同
- 2025年度珠寶行業(yè)人力資源外包合同
- 2025年度魚池租賃與漁業(yè)風(fēng)險(xiǎn)管理合同
- 2025年度廚師職業(yè)培訓(xùn)學(xué)院合作辦學(xué)合同4篇
- 《組織行為學(xué)》第1章-組織行為學(xué)概述
- 市場(chǎng)營銷試題（含參考答案）
- 2024年山東省泰安市高考物理一模試卷(含詳細(xì)答案解析)
- 護(hù)理指南手術(shù)器械臺(tái)擺放
- 腫瘤患者管理
- 四川省成都市高新區(qū)2024年七年級(jí)上學(xué)期語文期末試卷【含答案】
- 2025年中國航空部附件維修行業(yè)市場(chǎng)競(jìng)爭(zhēng)格局、行業(yè)政策及需求規(guī)模預(yù)測(cè)報(bào)告
- 國土空間生態(tài)修復(fù)規(guī)劃
- 2024年醫(yī)療器械經(jīng)營質(zhì)量管理規(guī)范培訓(xùn)課件
- DB11T 1136-2023 城鎮(zhèn)燃?xì)夤艿婪D(zhuǎn)內(nèi)襯修復(fù)工程施工及驗(yàn)收規(guī)程
評(píng)論
0/150
提交評(píng)論